Introduction
HIV protease inhibitors (PIs) are an important component of highly active antiretroviral therapy (HAART; reviewed in Wainberg and Jeang 1 ). However, the success of HIV treatment is hampered by the emergence of drug resistance 2, 3 and newer PIs with improved pharmacological profiles are needed. Various strategies including structure-based drug design have been used to develop new PIs 4, 5 and one such strategy maximizes the number of hydrogen bonds between a PI and the HIV-1 protease (PR) backbone, leading to activity against drug-resistant HIV. 4, 6 PIs with improved resistance profiles have also been developed using a solvent-anchoring approach 7 and a novel lysine sulphonamide-based molecular core. 8, 9 A survey of five PIs that quantitatively evaluated amounts of bound inhibitor outside the substrate envelope concluded that the exterior volume of the inhibitors correlated with a loss of affinity to mutant PR enzyme. 10 Darunavir is a highly efficient PI that is effective against many HIV variants that are resistant to other PIs. 11, 12 This is attributed to its high binding affinity for PR and the fact that darunavir binds tightly within the substrate envelope. 13 However, other PIs are needed and PL-100 is a novel lysinebased sulphonamide PI that is potent, specific and non-toxic, which was designed on the basis of structural data obtained for wild-type (wt) PR variants of HIV-1 group M, subtype B.
14 PL-100 has a favourable resistance profile and is active against many HIV variants that are resistant to other PIs. It is active against multiple HIV subtypes and requires an accumulation of at least three mutations in the flap region and active site of PR in order for resistance to PL-100 to occur. 15 -17 In the present study, we have determined the mutational profile, antiviral activity and structural binding of PL-100 compared with that of darunavir in HIV-1 subtype B. 
In vitro selection of resistance mutations in CBMCs and MT-2 cells
In vitro passage experiments were performed in the presence or absence of drug (PL-100, amprenavir and darunavir), as described previously. 17 Virus-containing culture fluids were harvested and kept at 2808C for subsequent genotypic analysis at the same time that drug concentrations were increased.
Nucleic acid extraction, amplification and sequencing analysis
Viral RNA was extracted from culture supernatants using the Qiagen QIAamp viral extraction kit (Mississauga, Ontario, Canada). PCR amplification was performed according to a previously published protocol (Virco BVBA, Mechelen, Belgium). The resulting PCR-amplified DNA fragments were purified using the QIAquick PCR purification kit and products were used as templates for nucleotide sequencing analysis. Genotyping was performed by sequencing a 325 bp fragment of HIV pol (positions 2253 -2578) spanning the entire PR using Virco primers (Virco BVBA, Mechelen, Belgium) with a BigDye Terminator sequencing kit (version 1.1; Applied Biosystems, Foster City, CA, USA) and automated sequencer (ABI Prism 3130 Genetic Analyzer; Applied Biosystems). The sequence of each sample was compared with that of the wt subtype B consensus virus and with data in the Stanford database (http://sierra2.stanford.edu/sierra/servlet/JSierra?action= sequenceInput). The isolates BK132 and 5326 were passaged in MT-2 cells for 66 passages.
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Phenotypic susceptibility to PIs in CBMCs and MT-2 cells
Antiviral activity was measured in cell culture-based phenotypic assays to determine the susceptibility of HIV-1 to different PIs (nelfinavir, saquinavir, amprenavir, lopinavir, atazanavir, darunavir and PL-100), as described elsewhere. 18 Briefly, cells were infected for 2 h with either wt or drugselected variants, washed to remove unbound virus and plated in duplicate into 96-well plates in the presence or absence of drug and incubated at 378C. For MT-2 cells, a cytopathic effect was confirmed on day 4 or 5 and supernatants harvested for reverse transcriptase (RT) activity. For CBMCs, cells were fed with fresh medium containing appropriate drug dilutions and RT assays were performed on day 7. EC 50 concentrations of PIs were determined from RT values. The preliminary clinical cut-off of PL-100 has been described elsewhere. 15 
Simulation of drug docking
The isomeric SMILES description for PL-100 was obtained from the twodimensional (2D) structure of PL-100 available on PubChem Compound (CID: 513956) and used to generate a three-dimensional (3D) structure using the program Avogadro version 1.0.3. 19 The same program was used to perform geometric optimization of unbound PL-100 with 500 Figure 2 . PR-inhibitor interactions calculated after docking simulations of (a) PL-100, (b) darunavir and (c) amprenavir to wt PR (grey ribbons) using AutoDock Vina. 24 Ligands are shown as transparent space-filling and solid stick models, coloured based on standard atomic coloration: red shows acidic oxygens and blue represents basic nitrogen atoms; polar hydrogens are shown in white. Hydrogen-binding interactions are shown by a solid black line and other residue-ligand contacts are shown by yellow-coloured carbon atoms on the ligand as well as by a solid green line for strong ligand-residue contacts. Determination of residue-ligand contacts and image processing was performed using UCSF Chimera. 28 This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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steps of steepest descent using the MMFF94 force field. 20 PubChem Compound was also the source of 3D structures for darunavir (CID: 213039) and a different PI, amprenavir (CID: 65016). All ligands were prepared as flexible docking ligands in AutoDock tools. 21 The protein databank (PDB) structures of wt PR 4DQB 22 and multidrug-resistant (MDR) PR (D25N, M36V and I84V) 1RPI 23 were prepared for docking by removal of cocrystallized ligands. Water molecules were retained for the subsequent docking simulations. The protein files were prepared as receptors using AutoDock tools. Each ligand was docked into the central cavity of the PR dimer using a grid cube measuring 20 Å in each of the x, y and z directions in AutoDock Vina. 24 Docking was repeated using DockingServer, 25 which uses AutoDock 4 docking parameters, and using the Lamarckian genetic algorithm and the Solis & Wets local search method. 21 The initial position, orientation and torsions of the ligand molecules were set randomly. All rotatable torsions were released during docking. Each docking study was derived from 10 different runs that were set to terminate after a maximum of 250000 energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å was used and quaternion and torsion steps of 5 were applied. A third set of dockings was carried out using SwissDock, 26 an online server that docks ligands to proteins using EADock DSS docking software and analyses poses by CHARMM c35b1 FACTS. 27 In all cases, the top-ranked results are considered. The molecular graphics programs UCSF Chimera 1.5.3 28 and PyMOL 23 were used for image analysis and processing.
Results
Development of resistance mutations to PL-100, amprenavir and darunavir in CBMCs and MT-2 cells
To further investigate the unique mutational pathway of PL-100, 16 the wt subtype B clone HIV-1/IIIB was selected for drug resistance in CBMCs with both PL-100 and amprenavir for 48 weeks. Genotypic analysis confirmed the unique resistance pathway of PL-100, such that a novel T80I mutation appeared first, followed by M46I and P81S. A novel K45R change was found in one of the isolates; this mutation has also been observed in patients receiving atazanavir. 29 Accumulation of multiple mutations under PL-100 drug pressure in culture was delayed compared with the selections with amprenavir, against which multiple mutations appeared quickly (Table 1) .
Five subtype B clinical isolates that contained six or fewer polymorphisms were also used in selections in CBMCs ( Table 2 ). All viruses passaged in the absence of drug (controls) were sequenced to confirm the absence of any additional mutations. The results show that two distinct resistance pathways are associated with PL-100, one of which involves the T80I mutation, -100  G48, D30, I50  D25  A28, V32, I47, I50, P81,  V82, I84  R8, D25, D29, D30,   DRV  D29  D25, D30  A28, V32, I47, I50, P81,  V82, I84   D25, D29, D30, T80, P81,  V82, I 84   APV  D29  R8, D25, D29,  D30  V32, I47, I50, I84  D25, A28, D29, D30, L23,  I50 , P81, V82, I84 PL-100 as an HIV-1 protease inhibitor while the other involves mutations at either positions 82 and 90 or both (Table 2) .
Two subtype B clinical isolates (BK132 and 5326) were used for selection in MT-2 cells (Table 2) . At baseline, BK132 displayed polymorphisms at positions I64V, V77I and I93L, while isolate 5326 harboured polymorphisms at positions E35D, M36I, R41K, L63P and H69Q. Tissue culture selection with PL-100 yielded the PR mutations R41K/R, M46L, L63P, V82A and L90M in isolate BK132, and L10I, N37S, K45I/K and I54M in isolate 5326 (Table 2) .
We also selected for darunavir resistance using two clinical isolates, 5331 and 5346, in CBMCs. After 40 weeks of passage using darunavir concentrations of 0.025 and 0.03 mM for 5331 and 5346, respectively, no mutations in PR were revealed by genotypic analysis.
Phenotypic susceptibility in CBMCs
All viruses selected in tissue culture were tested for susceptibility to PIs. Lower and upper clinical cut-offs for resistance of approved PIs were previously established as 1.2 -9.4 for nelfinavir, 1.5 -19.5 for amprenavir, 6.1 -51.2 for lopinavir, 2.5 -32.5 for atazanavir, 3.1-22.6 for saquinavir and 10-106.9 for darunavir. 30 The in vitro antiviral activity of relevant PIs against various PL-100-selected variants was tested in CBMCs at weeks 8, 20, 25 and 48 (Table 3 ). All viruses containing mutations had low-to high-level resistance to PL-100, but retained susceptibility to nelfinavir, lopinavir, saquinavir and darunavir (Table 3 ). The viruses selected after 8 and 25 weeks were susceptible to atazanavir, while those selected after weeks 20 and 48 showed a 2.9-and 2.4-fold decreased susceptibility, respectively, to atazanavir. Susceptibility to amprenavir was decreased by 6.5-and 3.3-fold in the case of variants selected at weeks 20 and 25, respectively, but full activity was retained with viruses selected at weeks 8 and 48.
One subtype B clinical isolate (5331) containing PL-100 mutations selected in CBMCs as well as two additional subtype B clinical isolates (BK132 and 5326) containing PL-100 mutations selected in MT-2 cells were phenotypically evaluated for PL-100 drug susceptibility (Table 4 ). In CBMCs, the 5331 isolate was highly resistant to PL-100 compared with other PIs (Table 4) . In MT-2 cells, isolates BK132 and 5326 were resistant to all PIs Asahchop et al.
tested except for darunavir, with fold changes (FCs) being above the lower clinical cut-off (Table 4) . Viruses containing the T80I mutation displayed only low-level resistance to the other PIs, while viruses containing V82A and L90M had high-level crossresistance against these drugs (Tables 3 and 4) .
Structural modelling of amprenavir, PL-100 and darunavir
We used available crystal structures in the protein databases, PDB ID: 4DQB 22 and PDB ID: 1RPI, to try to understand drug -PR interactions and the effect of mutations in the binding pocket on drug binding. 31 The multidrug-resistant (MDR) PR displays an enlarged drug-binding domain relative to wt PR (Figure 1) .
Using three independent approaches, three drugs (darunavir, amprenavir and PL-100) were docked into the wt structure ( (Figure 3a-d) . Identified PL-100 mutations all affect the hydrophobicity of the pocket, but do not specifically alter the binding of the inhibitor core to PR. Docking of all drugs to MDR PR resulted in different docked conformations with severely reduced binding, indicating low reliability of binding when the D25 and V84 mutations were present (Figure 4a-d) . The diphenyl group of PL-100 is flexible around its chiral centre and can adjust for changes in hydrophobicity fairly easily without losing its core contacts with I51 and D30.
Discussion
Although newer PIs, such as darunavir, have significantly improved response rates in patients with multiple drug resistance, there is still a need for robust new PIs with better pharmacokinetic and tolerability profiles. We previously showed that resistance to PL-100 in non-B HIV-1 subtypes can emerge via mutations at positions 82 and 90 or, alternatively, via a T80I substitution that appears to be unique to this drug. 17 The present data demonstrate that resistance-conferring mutations were rapidly selected in viruses passaged in the presence of PL-100, which apparently has a lower barrier for drug resistance than darunavir, for which no resistance mutations were selected over 40 weeks. The high genetic barrier and delayed accumulation of darunavir resistance mutations has also been observed by others. 32, 33 Viruses selected under PL-100 drug pressure showed low to high resistance to PL-100, but retained susceptibility to darunavir and saquinavir. PL-100 selected for mutations at positions R41K/R, M46L, L63P, V82A and L90M in isolate BK132, and L10I, N37S, K45I/K and I54M in isolate 5326. These mutations caused only a slight increase in the FC for darunavir.
Dimerization of HIV PR subunits is an essential process in the proteolytic activity of HIV PR. 34, 35 Darunavir can inhibit PR dimerization in vitro in addition to blocking PR activity, and this may contribute to its activity against multiple PI-resistant isolates. 36 Resistance mutations typically reduce the binding affinity of the inhibitor. 37 In the case of PR, more than one resistance mutation is usually needed for resistance to occur (Figure 1 ). In the case of amprenavir, the hydrogen bonding of amprenavir to the backbone of D30 is important, 4 while the THF ring of darunavir may increase its number of backbone interactions. 4 Here, we have shown that darunavir has a superior resistance profile to PL-100 and attribute this to its binding to the A28, D29 and D30 backbone via its di-THF groups (Figure 2a-c) . In contrast, PL-100 has diphenyl groups that bind through delocalized hydrophobic interactions. Thus, hydrogen-bonding contacts and the presence of the di-THF group in darunavir, as well as the hydrophobic nature of PL-100, are all important factors in drug binding. A high genetic barrier for drug resistance should be important in the design of new PIs. Redesigning the structure of PL-100 to include a di-THF group might improve its binding and antiviral activity.
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